BrainStorm Cell (BCLI) director receives 150,000 stock options at $0.70 strike

Rhea-AI Filing Summary

Bairu Menghisteab reported acquisition or exercise transactions in this Form 4 filing.

BRAINSTORM CELL THERAPEUTICS INC. director Menghisteab Bairu received a grant of stock options to buy 150,000 shares of common stock at $0.70 per share. These options, granted under the company’s 2014 Stock Incentive Plan, expire on February 26, 2036.

The award vests over a short schedule: 50% of the options vest on the grant date and the remaining 50% vest on the six-month anniversary, as long as Bairu remains employed by the company through each vesting date. Following this grant, Bairu holds 150,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bairu Menghisteab

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	150,000	$0.70	$105K

Holdings After Transaction: Stock Option (Right to Buy) — 150,000 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Key Figures

Options granted: 150,000 options Exercise price: $0.70 per share Underlying shares: 150,000 shares +2 more

5 metrics

Options granted 150,000 options Stock Option (Right to Buy) grant to director

Exercise price $0.70 per share Strike price for 150,000 underlying common shares

Underlying shares 150,000 shares Common stock underlying the option award

Post-transaction options held 150,000 options Total derivative holdings following this grant

Option expiration February 26, 2036 Expiration date of granted stock options

Key Terms

Stock Option (Right to Buy), 2014 Stock Incentive Plan, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2014 Stock Incentive Plan financial

"granted under the Issuer's 2014 Stock Incentive Plan"

vesting financial

"The Stock Options shall vest as to (i) 50% of the award"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-02-26T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bairu Menghisteab

(Last) (First) (Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	$0.7	02/26/2026		A		150,000		(2)	02/26/2036	Common Stock	150,000	$0.7(1)	150,000	D

Explanation of Responses:

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.

2. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Menghisteab Bairu	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BCLI director Menghisteab Bairu report on this Form 4?

Bairu reported receiving a grant of stock options for 150,000 shares of BrainStorm Cell Therapeutics common stock. The options were awarded as compensation under the company’s 2014 Stock Incentive Plan at an exercise price of $0.70 per share.

What is the exercise price and expiration date of the new BCLI stock options?

The granted stock options have an exercise price of $0.70 per share and expire on February 26, 2036. This means Bairu can buy BrainStorm Cell Therapeutics shares at $0.70 anytime before that expiration date, subject to vesting conditions.

How do the 150,000 BCLI stock options granted to Menghisteab Bairu vest?

The options vest in two steps: 50% of the 150,000-share award vests on the grant date and the remaining 50% vests six months later. Vesting is contingent on Bairu remaining employed by BrainStorm Cell Therapeutics through each applicable vesting date.

How many BCLI stock options does Menghisteab Bairu hold after this grant?

After this transaction, Bairu directly holds 150,000 stock options for BrainStorm Cell Therapeutics common stock. This total reflects the newly granted award reported in the Form 4 and represents his derivative holdings shown in this particular filing.

Are the new BCLI stock options for Menghisteab Bairu part of a specific incentive plan?

Yes, the options were granted under BrainStorm Cell Therapeutics’ 2014 Stock Incentive Plan. Such plans are typically used to align director and employee compensation with shareholder interests by granting equity-based awards like stock options subject to vesting requirements.